NasdaqGS:LEGNBiotechs
Can Legend Biotech’s (LEGN) US Expansion Shape Its Innovation Edge in CAR-T Therapies?
Legend Biotech recently celebrated the official opening of its new Philadelphia R&D facility, strengthening its innovation capabilities and expanding its footprint in the United States, with approximately 55 new full-time employees joining the team.
The company also reported third-quarter results showing a significant increase in revenue to US$272.33 million and a substantial reduction in quarterly net loss, reflecting operational progress and momentum behind its CAR-T therapy...